Autologous CSF-derived activated T cells

Autologous CSF-derived activated T cells are a form of personalized cell therapy in which T lymphocytes are isolated from a patient's own cerebrospinal fluid (CSF), expanded and activated ex vivo, and then reintroduced into the patient as a therapeutic vaccine. This approach has been primarily investigated for autoimmune diseases such as multiple sclerosis (MS). The process involves stimulating mononuclear cells from the patient's CSF with specific antigens (often myelin peptides), expanding antigen-specific CD4+ T helper cells—typically of Th1 or mixed Th0 subtype—and then irradiating them to prevent further proliferation before administration. These vaccines display heterogeneous reactivity toward myelin antigens such as MBP, PLP, and MOG. The intended mechanism is to induce anti-idiotypic immune responses that downregulate pathogenic autoreactive T cell clones involved in disease pathology[1][2].

Other names

autologous cerebrospinal fluid-derived activated T cellsCSF-T cell vaccineautologous CSF-T cell vaccine